Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

11 results about "Aspartic Acid Proteases" patented technology

A subclass of peptide hydrolases that depend on an ASPARTIC ACID residue for their activity.

Aspartic protease heat-resistant mutant and application thereof

PendingCN120424916AFungiHydrolasesAspartic protease activityEnzyme catalysis
The invention provides an aspartic protease heat-resistant mutant and application thereof. Wherein the aspartic protease heat-resistant mutant comprises (a) a protein which is based on wild type aspartic protease pap1 as shown in SEQ ID NO: 1, is subjected to amino acid mutation on at least one of the following sites: G133, D159, S376, T198, T103, T144, L303 or A387, has aspartic protease activity and has higher heat resistance than that of the wild type aspartic protease pap1; or (b) a protein which has more than 80% of homology with the amino acid sequence limited in (a), has aspartic protease activity and has heat resistance higher than that of wild type aspartic protease pap1. The aspartic protease can solve the problem of poor heat resistance of aspartic protease in the prior art, and is suitable for the field of enzyme catalysis.
Owner:ANGEL YEAST CO LTD +1

Egg allergy preventing agent or the like, and food composition containing same

The present invention provides highly effective and safe means capable of preventing or treating an egg allergy in infants. An oral immunotolerance agent or a food composition for preventing or treating an egg allergy according to the present invention contains a degraded product of heat-denatured egg white with an aspartic protease (e.g. pepsin) or a metal protease (e.g. thermolysin).
Owner:NAT CENT FOR CHILD HEALTH & DEV +1

Aspergillus niger, methods of making and using same, and methods of producing citric acid and / or succinic acid

The application relates to the field of genetic engineering, and discloses an Aspergillus niger, a construction method and application of the Aspergillus niger, and a method for producing citric acid and / or succinic acid. Aspergillus niger The Aspergillus niger is obtained by simultaneously overexpressing alpha-amylase and aspartic protease in a starting strain. The Aspergillus niger provided by the application can realize efficient degradation and conversion of starch by synergistically overexpressing amyA genes and pepA genes, solve the technical bottleneck that the original strain is limited in growth in a starch-based fermentation system and has insufficient acid production capacity, can efficiently produce succinic acid and citric acid by taking low-cost starch as the only carbon source, significantly reduce the industrial production cost of organic acid, and promote the green and sustainable upgrading of the fermentation industry.
Owner:NANJING NORMAL UNIVERSITY

Aspartic protease for treatment of gluten intolerance, nucleic acid molecules encoding the aspartic protease, method of producing the aspartic protease, and application thereof

ActiveUS12644109B2Peptide/protein ingredientsPeptidasesGluten intoleranceAspartic Acid Proteases
An aspartic protease and the use of the aspartic protease in the hydrolysis of gluten. This protease can hydrolyze gluten and the gluten-derived immunogenic peptides at pH 2.0˜4.0. Also provided are methods for the production of the aspartic protease, including recombinant plasmids, transformants, and a purification method thereof; methods of using the aspartic protease to prepare drugs and oral enzyme supplements for treatment of diseases or discomforts related to gluten ingestion, such as celiac disease; and a method of using the asparic protease in food-processing process to remove or reduce gluten in foods or beverages.
Owner:NATIONAL CHUNG HSING UNIVERSITY

Sugarcane ScGIP1 gene, encoded protein and application

The invention provides a sugarcane ScGIP1 gene, an encoded protein and application, and belongs to the technical field of genetic engineering. The nucleotide sequence of the ScGIP1 gene is as shown in SEQ ID NO. 1. The invention preliminarily reveals that the sugarcane aspartic protease ScGIP1 as a novel plant disease-resistant factor has potential application value in improvement of plant disease resistance, enriches functional cognition of aspartic protease in plant immune response, provides potential gene resources for disease prevention and control of sugarcane and other crops, and has broad application prospects. Good application prospects and popularization values are realized.
Owner:GUANGXI UNIV

Aspartic protease mutants and their applications

ActiveCN119931997BFungiBacteriaAspartic protease activityAspartic Acid Proteases
The present invention provides an aspartic protease mutant and its applications. The aspartic protease mutant includes: 1) a protein having an amino acid sequence with mutations at at least one of the following sites in SEQ ID NO: 4: R110, S38, S51, Q134, N169, V182, A183, V250, R322, N101, T113 or Q239, and having aspartic protease activity; or 2) a protein having an amino acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% or more homology with the protein in 1), and having aspartic protease activity. Compared with the wild-type aspartic protease, the aspartic protease mutant of the present invention has the advantages of high specific activity and strong thermal stability, which is helpful for its wide application in the fields of food, medicine, feed and leather, etc.
Owner:ANGEL YEAST CO LTD

A Rhizomucor miehei aspartic protease with coagulating activity, its preparation method and application

ActiveCN115558655BMicroorganism based processesCheese manufactureHeterologousAspartic Acid Proteases
The present invention discloses an aspartic protease from Rhizomucor miehei with rennet activity, its preparation method and application. The expression plasmid of this aspartic protease is constructed and transformed into Aspergillus niger for heterologous expression. The protease activity of the fermentation broth of the recombinant Aspergillus niger strain reaches 2000 U / mL, the protein content is 6.1 mg / mL, the optimal pH is 2.5, the optimal temperature is 40 °C, and it maintains a relatively high enzyme activity below 45 °C, and its substrate specificity is wide. This enzyme has a significant renneting effect, the rennet activity is 3894.1 SU / mg, and it specifically hydrolyzes the peptide bonds of Lys22-Ile23, Leu33-Ser34, Leu51-Ile52, Lys64-Pro65 and Phe105-Met106 of κ-casein. The aspartic protease of the present invention has good application value in the fields such as cheese making.
Owner:CHINA AGRI UNIV

Application of Protein IbNFYA3 in Regulating Resistance to Sweet Potato Soft Rot

ActiveCN119775379BPlant peptidesFermentationBiotechnologyAspartic Acid Proteases
The present invention relates to the field of biotechnology, in particular to the application of the protein IbNFYA3 in regulating the resistance of sweet potato to soft rot. The present invention discovers for the first time that overexpressing the NFYA gene in plants can significantly increase the content of jasmonic acid and aspartic protease, thereby being able to effectively resist soft rot pathogens. Specifically, the present invention provides an IbNFYA3 gene encoding an NFYA transcription factor (protein IbNFYA3). After introducing this gene into sweet potato, transgenic sweet potato plants overexpressing the IbNFYA3 gene are obtained. When the transgenic sweet potato tubers are identified for their resistance to soft rot, it is found that compared with wild-type sweet potato, the transgenic sweet potato tubers have significantly enhanced resistance to soft rot. Thus, it can be seen that the IbNFYA3 protein and its encoding gene of the present invention can regulate the resistance of plants to soft rot and can be used to cultivate transgenic plants with high disease resistance.
Owner:CHINA AGRI UNIV

Modified proteins

The present invention relates to the field of modified proteins, immunogenic compositions and vaccines comprising said modified proteins, their preparation and the use of such compositions in medicine. More specifically, the present invention relates to a modified Sap2 (Secretory Aspartic Protease 2 of Candida albicans) protein. The modified Sap2 protein can be used as other antigens, in particular as a carrier protein for carbohydrate antigens or other antigens lacking T cell epitopes.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA

Drug delivery systems comprising neurotrophic agent, apoptosis signaling fragment inhibitor (FAS) or fas ligand (FASL) inhibitor, tumor necrosis factor-α (TNF-α) or TNF receptor inhibitor, mitochondrial peptide, oligonucleotide, chemokine inhibitor, or cysteine-aspartic protease

PendingJP2025159233ASenses disorderNervous disorderAspartic Acid ProteasesRenal infarction
To provide a drug delivery system to treat a medical condition such as an inherited or age-related choroid, retina, optic nerve disorder, or optic nerve degeneration; an otic disorder; a neurologic or CNS disorder; or a related condition; or a condition related to occlusion or obstruction of a blood vessel or blood circulation such as a stroke, myocardial or renal infarction.SOLUTION: A drug delivery system comprises a first active pharmaceutical ingredient (API) and a sustained delivery component, wherein the first API is a peptide derivative of ciliary neurotrophic factor (CNTF) comprising the peptide sequence DGGL, and the first API is a peptide represented by SEQ ID NO: 2 (peptide 21: Ac-DGGLAG-NH2). The drug delivery system is used for injection into mammal eyes.SELECTED DRAWING: None
Owner:セラセラピューティクスエルエルシー